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The use of human pluripotent stem cells (hPSCs) in
cell therapy is hindered by the tumorigenic risk from
residual undifferentiated cells. Here we performed
a high-throughput screen of over 52,000 small mole-
cules and identified 15 pluripotent cell-specific inhib-
itors (PluriSIns), nine of which share a common struc-
tural moiety. The PluriSIns selectively eliminated
hPSCs while sparing a large array of progenitor and
differentiated cells. Cellular and molecular analyses
demonstrated that the most selective compound,
PluriSIn #1, induces ER stress, protein synthesis
attenuation, and apoptosis in hPSCs. Close exami-
nation identified this molecule as an inhibitor of
stearoyl-coA desaturase (SCD1), the key enzyme in
oleic acid biosynthesis, revealing a unique role for
lipid metabolism in hPSCs. PluriSIn #1 was also
cytotoxic to mouse blastocysts, indicating that the
dependence on oleate is inherent to the pluripotent
state. Finally, application of PluriSIn #1 prevented
teratoma formation from tumorigenic undifferenti-
ated cells. These findings should increase the safety
of hPSC-based treatments.
INTRODUCTION
Human pluripotent stem cells (hPSCs) hold great promise for
regenerative medicine due to their unique abilities to self-renew
and to differentiate into all the cell types of the human body.
However, the same properties also make these cells tumori-
genic, and therefore tumor formation was found to positively
correlate with the residual presence of undifferentiated pluripo-
tent cells (Miura et al., 2009). As very few hPSCs are sufficient
for teratoma formation (Hentze et al., 2009; Lee et al., 2009),
it is essential to eliminate residual pluripotent cells prior to theCeclinical application of their derivatives (Ben-David and Benve-
nisty, 2011). Importantly, while the generation of induced plurip-
otent stem cells (iPSCs) may have resolved the problem of
immunogenic rejection, the risk of teratoma formation remains
a major obstacle that is equally relevant for embryonic stem cells
(ESCs) and for iPSCs (Ben-David and Benvenisty, 2011; Miura
et al., 2009).
To promote the removal of residual pluripotent cells from
differentiated cultures, several strategies have been suggested,
including introduction of suicide genes (Schuldiner et al., 2003),
interference with tumor progression genes (Blum et al., 2009) or
with tumor suppressors (Menendez et al., 2012), cell sorting
based on antibodies against PSC-specific surface antigens
(Tang et al., 2011), and the use of cytotoxic antibodies (Choo
et al., 2008). However, these methods are largely based either
on geneticmanipulations or on cell sorting, which are not optimal
for cell therapy purposes. Furthermore, no single antibody or
cycle of cell sorting completely removes undifferentiated cells
from mixed cultures. Thus, current clinical trials largely depend
on differentiation of human ESCs, using compounds that affect
pathways such as BMP or TGFb, with the hope that these
differentiation protocols will minimize the residual existence of
undifferentiated cells. Many preclinical trials in animals, however,
demonstrate that even after long-term differentiation protocols,
residual undifferentiated cells may still form tumors (Germain
et al., 2012; Roy et al., 2006; Wernig et al., 2004; Xie et al.,
2007). A more robust method for the elimination of undifferenti-
ated hPSCs from culture is therefore required.
In order to identify small molecules that selectively perturb vital
pathways in hPSCs, and thus induce cell death only in these
cells, we designed and performed an unbiased high-throughput
screen of small molecules. The desired small molecules should
eliminate efficiently and robustly undifferentiated hPSCs from
culture, without affecting their differentiated derivatives. Applica-
tion of these small molecules to cultures of differentiated cells
prior to their transplantation into patients would therefore
decrease, and possibly abolish, the risk of tumor formation due
to residual undifferentiated cells. A major advantage of this
approach is that it does not require genetic manipulations orll Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Inc. 167
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Selective Inhibitors of hPSCs Identified in an HTSsingle-cell dissociation, so that genetically normal hPSCs can be
induced to differentiate into complex structures, which need not
be disassembled prior to their transplantation.
RESULTS
Assay Development for High-Throughput Screen
Prior to the primary screen, we developed and optimized
a protocol that enables the culture of undifferentiated hPSCs
in a 384-well format, the automatic application of smallmolecules
to these cell plates, and the accurate assessment of cell viability
after the exposure of the cells to the compounds. Human
ESCs and iPSCs were grown on matrigel-coated plates without
feeders, using a serum-free defined medium (mTeSR1) (Ludwig
et al., 2006). The pluripotency of the cells under these conditions
was confirmedby their normalmorphology, their positive staining
for alkaline phosphatase (AP), and their expression of OCT4 (see
Figures S1A andS1B available online). Cells were then harvested
and seeded in 384-well plates, at a density of 5,000 cells per well.
The cells maintained their normal morphology, formed colonies,
and proliferated. Quantitative PCR and immunofluorescence
(IF) staining for OCT4 verified that the cells remained undiffer-
entiated for at least 5 days under these conditions (Figures S1C
and S1D). For the accurate measurement of the number of
viable cells in culture, an ATP-based luminescent cell viability
assay (CellTiter-Glo) was applied. We verified in our undifferen-
tiated cells that this assay accurately determines the number of
viable cells in culture (Figures S1E and S1F). We also performed
apilot screenwith 50knowncytotoxic compounds (TableS1) and
selected two compounds as controls for the primary screening:
amsacrine hydrochloride, a DNA topoisomerase inhibitor, and
cyclohexamide, a translation inhibitor (Figures S1G and S1H).
High-Throughput Screen Identifies Cytotoxic Inhibitors
of hPSCs
In order to identify potent cytotoxic inhibitors of hPSCs, we
screened 52,448 small molecules against undifferentiated
human ESCs. These molecules constitute a representative
subset of the Hoffmann-La Roche compound library, comprised
of diverse chemical entities (see Supplemental Experimental
Procedures). Diploid human ESCs, CSES2 cells, were grown
on matrigel-coated plates with the defined medium mTeSR1,
their pluripotency was verified, and they were plated in 384-
well plates. Twenty-four hours after cell plating, cells were
exposed to the compounds, so that each of the 52,448
compounds was added to one well, at a final concentration of
20 mM (with 0.5% DMSO). Twenty-four hours after compound
addition, cell viability was measured in each well. A schematic
flow chart of the primary screen is presented in Figure 1A, and
representative plate results are presented in Figure 1B.
The primary screen was very robust, as determined by its high
Z’ factor (0.78 ± 0.06, Figure S1I). ‘‘Hits’’ were defined as
compounds that induced over 60% reduction in the number of
viable cells. Using this threshold, 2,031 compounds (<4% of
the tested compounds) were selected (Figure 1C). As the primary
screen was performed at a single concentration and without
replicates, the first confirmation screen was performed to re-
move false positive hits. Screening replicates of two indepen-
dently derived human ESC lines (CSES2 and H9) at a single168 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Incconcentration (20 mM) confirmed 696 hits that were cytotoxic
for both cell lines (Figures 1D and 2B). Next, these 696 confirmed
hits were tested against the human ESC line CSES2, and its
clone CSES2-SO2/3, at eight concentrations (ranging from
50 mM to 23 nM, with 1:3 serial dilution steps). As expected,
the cytotoxic effect of the compounds was dose dependent
in >98% of the cases, and very high compound potency corre-
lations were observed between all of the human ESCs tested
(Figures 1D and 1E). To verify that the inhibitory effect of the
compounds persists over time, we exposed CSES2 cells to six
concentrations for 48 hr. The effect was maintained for all of
these compounds, without any recovery observed (Figure S1J).
We then examined the effect of the compounds on human
iPSCs. BJ-iPS28 cells were grown in the exact same conditions
as the ESCs and were tested at six concentrations (ranging
from 50 mM to 200 nM, with 1:3 serial dilution steps). The EC50
values (i.e., the effective concentrations that induce 50%
reduction in cell number) obtained for the iPSCswere very similar
to those of the ESCs, and no compounds were found to be
cytotoxic toward one cell type without having a detrimental
effect on the other (Figure 1F). Together, these data indicate
that the identified compounds are indeed potent cytotoxic
inhibitors of hPSCs.
Counter Screens Reveal Pluripotent-Specific Inhibitors
Next, we wanted to discover whether among the identified
compounds some would be cytotoxic only toward hPSCs and
not toward other cell types. We thus screened these 696
compounds against nine other cell types, representative of all
germ layers and developmental stages (Figure 2A). Importantly,
many of these cell types were differentiated from human ESCs or
iPSCs. The screened cell types included ESC-derived neural
stem cells (NSCs), ESC-derived mesenchymal stem cells
(MSCs), ESC-derived endodermal progenitor cells, ESC-derived
hepatocytes, iPSC-derived cardiomyocytes, fibroblasts from
which the iPSC cell line BJ-iPS28 was derived, and three cancer
cell lines: neuroblastoma (Kelly), cervical cancer (HeLa), and
hepatocarcinoma (Huh7). Each cell type was screened in either
a duplicate or a triplicate at 20 mMconcentration. Encouragingly,
the compound potency correlation between hPSCs and each of
the other cell types was much weaker than that within hPSCs
(Figures 2B and S2A–S2F). Unsupervised hierarchical clustering
was performed using the compound inhibition profiles of all cell
types. The result suggested that hPSCs indeed clustered
together by their response to small molecules and revealed
a subgroup of compounds highly cytotoxic specifically to these
cells (Figure 2C).
In order to further verify the selective cytotoxicity of identified
compounds, we screened them in multiple concentrations
against differentiated cells that were genetically matched to
the undifferentiated cells in our screen. CSES2-SO2/3 is a
genetically labeled cell line that expresses mCherry under the
promoter of the pluripotency hallmark geneOCT4 and enhanced
green fluorescent protein (EGFP) under the promoter of the early
endodermal marker SOX17 (Kopper and Benvenisty, 2012).
Therefore, these cells are red while undifferentiated and become
green when they differentiate into endodermal progenitors
(Kopper and Benvenisty, 2012) (Figures S3A–S3C). Both the
undifferentiated red cells and the differentiated green cells.
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Figure 1. High-Throughput Screening of 52,448 Small Molecules against hPSCs
(A) A schematic representation of the primary screen flow chart.
(B) Representative results of one assay plate. NC, negative control, 0.5% DMSO; TC50, toxic compound that leads to50% cell death, cyclohexamide at 2 mM;
PC, positive control, amsacrine hydrochloride at 5 mM. ‘‘Hits’’ were determined as compounds that induced over 60% reduction in the number of viable cells.
(C) A distribution plot of compound effect on cell viability. Arrow indicates the cutoff value; ‘‘hits’’ are marked in red.
(D) A three-dimensional scatterplot showing the response of three ESC lines to 2,031 compounds tested in a confirmation screen, at 20 mM concentration.
(E) A scatterplot comparing pEC50 values of 696 confirmed ‘‘hits’’ between two ESC lines: CSES2 and SO2/3. EC50 represents the half-maximal effective
concentration value; pEC50 = logEC50; correlation coefficient (r
2) = 0.80.
(F) A scatterplot comparing pEC50 values of 696 confirmed ‘‘hits’’ between ESC and iPSC lines (CSES2 and BJ-iPS28, respectively); correlation coefficient (r
2) =
0.57. See also Figure S1 and Table S1.
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values could be calculated for these genetically identical cells
(Figure 2D). Finally, we also screened at six concentrations the
BJ fibroblasts from which the iPSC line BJ-iPS28 was derived
and could thus generate reliable EC50 values for both the iPSCs
and their somatic cells of origin (Figure 2D).
We set a very stringent threshold and identified compounds
that induced above 80% inhibition in all of the hPSCs (at
20 mM) but less than 20% inhibition in other cell types (at the
same high concentration). Moreover, we required the EC50
values to be around 5 mM or lower for CSES2, CSES2-SO2/3,
and BJ-iPS28 but higher than 50 mM for the eight day-differenti-
ated CSES2-SO2/3 cells and for the BJ fibroblasts. Fifteen com-
pounds met or approached these stringent criteria (Figure 2E
and Table S2), and we thus termed them pluripotent-specific
inhibitors (PluriSIns). Human ESCs lose their sensitivity to Pluri-
SIns upon their differentiation, whereas human somatic cells
acquire this sensitivity upon their reprogramming to iPSCs
(Figures 2F and S3D). Considering the short exposure duration
used in our screen (24 hr) and the stringent threshold used for
‘‘hit’’ identification (>80% reduction in number of viable cells),
we reasoned that the identified compounds could not be prolif-
eration inhibitors but rather were cytotoxic compounds that
actively eliminated hPSCs. In order to confirm the cytotoxic
effect of PluriSIns in additional assays, cells were treated withCePluriSIns and subjected to (1) ATP-independent methylene
blue viability assay and (2) high-content microscopy imaging.
Both independent assays confirmed the cytotoxicity of the
PluriSIns toward hPSCs (Figures S4A and S4B).
In order to further verify the selectivity of the PluriSIns, we took
advantage of the genetic labeling system described above.
Undifferentiated and differentiated CSES2-SO2/3 cells were
subjected to microscopy imaging after exposure to PluriSIns.
This visualization verified the pluripotent-specific effect of
PluriSIns, independently of the ATP-based viability assay, as
the compounds clearly eliminated the red undifferentiated
cells, without any detectable effect on the green differentiated
cells (Figure 2G). Taken together, PluriSIns had a robust, rapid,
and selective cytotoxic effect toward hPSCs.
PluriSIn #1 Mechanism of Action
Examination of the chemical structure of PluriSIns (Figure 3A)
revealed that nine out of the 15 compounds share a common
structural moiety, phenylhydrazine (Ph–N[H,C]–NH). This is an
60-fold overrepresentation of this moiety compared to the
entire screening library (p < 1016). Moreover, seven of these
compounds share a more complex structure and can be defined
as N-acyl phenylhydrazine derivatives (Ph– N[H,C]–NH–(C = C)
n–[C,S] = [O,N], n = 0 or 1). This similarity may be linked to the
mechanism of action or to the specificity of these PluriSIns.ll Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Inc. 169
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Figure 2. Identification of Pluripotent-Specific Inhibitors
(A) A schematic representation of the cell types used for the counter screen. Four PSCs and nine cell types of all germ layers and developmental stages were
screened with the confirmed hPSC cytotoxic inhibitors from the primary screen.
(B) Scatterplots comparing the response to the 696 confirmed ‘‘hits’’ between the ESC line CSES2 and another ESC line (H9, top) or between CSES2 and
iPSC-derived cardiomyocytes (bottom). Very high correlation exists between the pluripotent cells (r2 = 0.87), whereas no correlation exists between the
pluripotent and differentiated cells (r2 = 0.03), demonstrating that many of the identified compounds are selectively cytotoxic toward human pluripotent stem
cells (encircled in red).
(C) Unsupervised hierarchical clustering of all cell types based on their cytotoxic response to the confirmed ‘‘hits’’ at 20 mM concentration, showing that human
pluripotent stem cells cluster together. Fifteen selective inhibitors of hPSCs (termed PluriSIns) were identified (yellow rectangle). Red and black represent high
(100%) and low (0%) inhibition values, respectively.
(D) Scatterplots comparing pEC50 values of all confirmed ‘‘hits’’ between the human ESC line CSES2-SO2/3 and the endodermal progenitor cells (EPCs)
differentiated from the same cell line (left; r2 = 0.05) and between the human iPSC line BJ-iPS28 and the fibroblasts from which it was derived (right; r2 < 0.01).
Note that in both cases many compounds were found to be cytotoxic selectively toward the undifferentiated cells.
(E) A summary of the screen phases, the cell types used, the number of compounds tested, and the number of compounds identified in each phase.
(F) Representative dose response curves of PluriSIn #1, showing that ESCs lose their sensitivity to this compound after 8 days of differentiation (top), whereas
somatic cells acquire such sensitivity upon their reprogramming to iPSCs (bottom).
(G) Fluorescence microscopy imaging, showing the differential response of undifferentiated cells (red), eight day-differentiated EPCs (green) and a mixed culture
of undifferentiated and differentiated cells (nuclear staining in blue, undifferentiated cells in red) to PluriSIn #1 (at 20 mM). Scale bars represent 100 mm.
See also Figures S2–S4 and Table S2.
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explored the most potent and selective compound, PluriSIn #1
(also known as isonicotinic acid N’-phenyl-hydrazine), and
another N-acyl phenylhydrazine derivative, PluriSIn #6. We
applied a toxicogenomic approach to identify gene expression
alterations after the exposure of the cells to the compounds.
Unsupervised hierarchical clustering based on global gene170 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Incexpression profiling revealed marked gene expression changes
in the PluriSIn-treated undifferentiated cells compared to their
DMSO-treated controls, 12 hr after exposure to the compounds
(Figure 3B).
Among the most deregulated genes, we detected several
hallmark genes related to apoptosis (Figure 3C). Functional
annotation analysis of deregulated genes (>2-fold change) was.
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Figure 3. PluriSIn #1 Induces ER Stress, Protein Synthesis Attenuation, and Apoptosis in hPSCs
(A) The chemical structure of the 15 identified PluriSIns. Phenylhydrazine, a common moiety shared by nine of these 15 compounds, is marked in red.
(B) Gene expression-based unsupervised hierarchical clustering of undifferentiated ESCs and eight day-differentiated endodermal progenitor cells, treated with
PluriSIn #1, PluriSIn #6, or without treatment (DMSO control). The heat map presents all differentially expressed genes (>2-fold) between control and treatment
conditions.
(C) Gene expression fold change of selected genes related to apoptosis, in undifferentiated ESCs and in eight day-differentiated endodermal progenitor cells,
12 hr after their exposure to PluriSIn #1 or PluriSIn #6 (20 mM).
(D) Representative FACS analysis of undifferentiated cells under DMSO control conditions (top) or exposed to PluriSIn #1 (20 mM, bottom) for 16 hr, confirming
that exposure to PluriSIn #1 induces apoptosis in the cells.
(E) Quantification of the increase in early and late apoptotic cells. Data are presented as mean ± SD.
(F) Immunoblots with an antibody against caspase-3, showing elevated activation in ESCs treated with PluriSIn #1 (20 mM). b-catenin is presented as loading
control; dithiothreitol (DTT) is presented as positive control.
(G) Quantification of cell viability after 24 hr exposure of human ESCs to PluriSIn #1 (20 mM) in the presence or absence of the pancaspase inhibitor Z-VAD-FMK.
Data are presented as mean ± SD.
(H) Gene expression fold change of selected genes related to ER stress, in undifferentiated ESCs and in eight day-differentiated endodermal progenitor cells,
12 hr after their exposure to PluriSIn #1 or PluriSIn #6 (20 mM). Gene expression change conferred by the general ER stress inducer DTT is presented as positive
control.
(I) Top: quantitative PCR analysis of the spliced variant of XBP1 (sXBP1), a hallmark of the unfolded protein response, in undifferentiated ESCs and in differ-
entiated fibroblasts. RPB1 was used as endogenous control. Data are presented as mean ± SD. Bottom: immunoblots with an antibody against phosphorylated
eIF2a (phospho-eIF2a), showing elevated phosphorylation level in ESCs treated with PluriSIn #1 but not in differentiated cells treated with the compound.
a-tubulin is presented as loading control; in both experiments, DTT (1 mM) is presented as positive control.
(J) The list of ten compounds ranked by the connectivity map asmost similar to PluriSIn #1, in terms of the global gene expression changes they confer. Themean
connectivity score represents the degree of similarity (on a scale of1 to 1). Protein synthesis inhibitors are denoted with red asterisks and are overrepresented in
this list (65-fold enrichment, p < 0.0001). Black asterisks denote compounds that are not defined in cmap as protein synthesis inhibitors but are known to
attenuate protein translation.
(K) Relative incorporation of S35-labeled methionine in ESCs and in differentiated fibroblasts, 12 hr after their exposure to PluriSIn #1 (20 mM) or to DMSO control
conditions. Data are presented as CPMA reads normalized to the total protein quantity. These results indicate that PluriSIn #1 induces protein synthesis
attenuation in hPSCs but not in differentiated cells. The general protein synthesis inhibitor cyclohexamide (10 mM) is presented as positive control. Data are
presented as mean ± SD. See also Figure S5.
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et al., 2009) and revealed enrichment for apoptosis (2.7-fold
enrichment, p = 0.007 after Benjamini correction). We therefore
performed an Annexin V apoptosis assay after 16 hr and 18 hr
exposure of undifferentiated cultures to PluriSIn #1, revealing
a gradual and significant increase in the percentage of apoptotic
cells in culture (Figures 3D, 3E, and S5A). Moreover, immuno-
blotting with a specific antibody against caspase-3 demon-
strated the activation of this hallmark executioner of apoptosis
after PluriSIn #1 treatment (Figure 3F). Lastly, exposure of
hPSCs to PluriSIn #1 in the presence of the pancaspase inhibitor
Z-VAD-FMK significantly suppressed PluriSIn #1-induced cell
death (Figure 3G). Together, these results confirm that apoptosis
is the central cell death mechanism activated by PluriSIn #1.
Among the most deregulated genes, we also detected
multiple genes related to endoplasmic reticulum (ER) stress
and unfolded protein response (UPR) (Figure 3H). The most
upregulated gene after PluriSIn treatment was CHOP (also
known as DDIT3), a hallmark of UPR (9-fold increase, p =
0.01). To further examine UPR in our system, we studied two
of its hallmarks: XBP1 mRNA splicing and phosphorylation
of eIF2a (Hetz, 2012). Quantitative PCR revealed 3.5-fold
increase in the expression of the spliced isoform sXBP1 after
exposure of hPSCs to PluriSIn #1 (p = 0.007, Figure 3I, top);
immunoblotting with a specific antibody against phosphorylated
eIF2a showed a marked increase of phosporylation (Figure 3I,
bottom). Thus, these assays confirmed that PluriSIn #1 leads
to ER stress in hPSCs.
We then applied the gene expression data to the connectivity
map (cmap), a database of genome-wide transcriptional ex-
pression data from cultured human cells treated with bioactive
small molecules (Lamb et al., 2006). Cmap was developed
to facilitate the discovery of pathways perturbed by small
molecules of unknown activity, based on the common gene
expression changes that similar small molecules confer (Lamb
et al., 2006). We thus queried this database with the deregulated
gene lists, i.e., the lists of genes that were at least 2-fold up-
regulated or downregulated after a 12 hr treatment with PluriSIn
#1. ER stress does not appear as a distinct category in the cmap
database (Iorio et al., 2010). However, this analysis indicated that
PluriSIns are most similar to protein synthesis inhibitors (PSIs),
as PSIs were ranked highest in the list, with very high connec-
tivity scores (Figure 3J). Only four compounds are classified as
bona fide PSIs in the cmap database (Iorio et al., 2010), and all
of them appeared among the ten most similar compounds to
PluriSIn #1 (65-fold enrichment, p < 0.0001). As ER stress can
indeed lead to translational attenuation, we tested directly the
effect of PluriSIn #1 treatment on protein synthesis. Using
a pulse-chase radioactive labeling assay, we measured the
incorporation of 35S-Met into the cells in the presence or
absence of PluriSIn #1. The results confirmed that PluriSIn #1
induces 30% decrease in protein synthesis in hPSCs (p =
0.005, Figure 3K). Importantly, no apoptosis, ER stress, or trans-
lation attenuation could be detected in differentiated cells
exposed to PluriSIn #1 (Figures 3C, 3H, 3I, and 3K). Moreover,
no significant gene expression change was induced in cells
exposed to PluriSIn #1 after merely 8 days of differentiation (Fig-
ure 3B), showing that the transcriptional landscape of differenti-
ated cells is not hindered by exposure to this compound. Thus,172 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Incwe confirmed that upon exposure to PluriSIn #1, undifferentiated
cells are selectively destroyed, whereas differentiated cells
remain intact.
Inhibition of SCD1 Underlies the Cellular Response
to PluriSIn #1
All of the 15 PluriSIns had been previously screened at Roche
and had never come up as cytotoxic. One of these nonrelated
screens, performed in the context of drug discovery of metabolic
disorders, was a biochemical screen aimed to identify inhibitors
of stearoyl-coA desaturase (SCD1), an ER-membrane protein
that is the key enzyme in the biosynthesis of monounsaturated
fatty acids (MUFAs). The compounds in that screen were tested
in a radiometric assay that monitors the formation of 3H-water
from the SCD1-catalyzed desaturation of 3H (9,10) stearoyl-
CoA to oleoyl-CoA, using murine liver microsomes as the source
of the enzyme (Miyazaki et al., 2000). When we searched Roche
databases for the 15 identified PluriSIns, we noticed that three
of them, including PluriSIn #1, had come up as ‘‘hits’’ in that
direct SCD1 inhibition assay. Inhibition of SCD1 was recently
shown to induce ER stress and UPR in some human cancer
cell lines, leading to apoptosis of these cells, and was thus
suggested to be a potential target for cancer therapy (Hess
et al., 2010; Mason et al., 2012; Minville-Walz et al., 2010;
Roongta et al., 2011). SCD1 is expressed in hPSCs (Assou
et al., 2007), but its role in these cells has not been described
to date. The similarity between the hPSC response to PluriSIn
#1 and the response of some cancer cell lines to SCD1 inhibitors
led us to explore whether SCD1 inhibition may underlie the
cellular response of hPSCs to PluriSIn #1.
We therefore compared the gene expression changes that
we observed in hPSCs after their exposure to PluriSIn #1, with
those previously detected in a human cancer cell line (H1299)
after the pharmacological inhibition of SCD1 by its specific
inhibitor A939572 (Roongta et al., 2011). We observed an
intriguing similarity between the expression changes: 12 of the
18 genes that exhibited significant expression changes in the
study of Roongta et al. (p < 0.05, >2-fold change), many of which
related to the ER stress pathway, were also significantly de-
regulated in our cells (Figure 4A). In order to directly examine
whether PluriSIn #1 inhibits SCD1 activity in pluripotent cells,
we performed a pulse-chase labeling assay. Human ESCs
were treated with PluriSIn #1 for 12 hr and were then labeled
with [1-14C] stearic acid, the substrate of SCD1, in the presence
of the compound. After 4 hr of incubation, lipids were purified
from the cells and separated by TLC. The enzymatic activity
was then evaluated by direct measurement of the radioactive
intensities of SCD1 substrate and product, [1-14C] oleic acid.
The results showed an 65% decrease in SCD1 activity after
the exposure of hPSCs to PluriSIn #1, in comparison to its
activity in DMSO-treated control cells (p = 2.13 106, Figure 4B).
These results indicate that PluriSIn #1 indeed inhibits SCD1
activity in hPSCs.
To validate that SCD1 inhibition can really lead to cell death in
hPSCs, we abolished its activity both pharmacologically and
genetically: treatment of human ESCs either with structurally
distinct specific SCD1 inhibitors (A939572 and CAY10566) or
with specific siRNAs against SCD1 resulted in massive cell
death (>80% decrease in cell viability on exposure to A939572.
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Figure 4. Inhibition of SCD1 Activity Underlies the Cellular Response of hPSCs to PluriSIn #1
(A) Gene expression fold change of the 18 genes previously identified to be upregulated or downregulated upon treatment of cancer cells (H1299) with A939572,
a specific inhibitor of SCD1 (Roongta et al., 2011). A similarity was found between the effect of SCD1 inhibitor on cancer cells to that of PluriSIn #1 on hPSCs
but not on eight day-differentiated cells.
(B) Direct measurement of SCD1 enzymatic activity in undifferentiated hPSCs treated with control DMSO or with PluriSIn #1 (20 mM), confirming that PluriSIn #1
inhibits SCD1 activity in hPSCs. Data are presented as mean ± SD.
(C) Quantification of the relative number of viable human ESCs under DMSO control conditions and after treatment with the SCD1 inhibitors A939572 or
CAY10566 (75 nM), in the presence or absence of oleic acid (100 mM). Data are presented as mean ± SD.
(D) Quantification of the relative number of viable human ESCs transfected with mock-siRNA or with siRNA against SCD1. Data are presented as mean ± SD.
(E) Quantification of the relative number of viable human ESCs under DMSO control conditions or after treatment with PluriSIn #1 (20 mM), in the presence
or absence of oleic acid conjugated to BSA. Oleic acid rescued the PluriSIn #1-induced cell death in a dose-dependent manner (red), while not affecting the
growth of control cells (green) and not rescuing the cell death induced by amsacrine hydrochloride (light blue). Note that BSA alone did not rescue PluriSIn
#1-induced cell death (light purple) and did not affect the growth of control cells (dark purple).
(F) Representative images of hPSCs treated with PluriSIn #1 (20 mM) and with increasing concentrations of oleic acid. An image of the cells under DMSO control
conditions is presented for reference. Scale bar represents 100 mm. See also Figure S5.
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Selective Inhibitors of hPSCs Identified in an HTSand CAY10566 and 70% decrease after knockdown; p = 6 3
106, 2 3 105, and 2 3 103, respectively), confirming that
hPSCs depend on MUFA synthesis for their survival (Figures
4C and 4D). Remarkably, exogenous supplementation of oleic
acid, the direct product of SCD1 activity, rescued the cell death
induced by these pharmacologic and genetic perturbations
(Figures 4C and 4D; p = 3 3 104, 1 3 104, and 6 3 103,
respectively).
We reasoned that if PluriSIn-induced apoptosis in hPSCs
occurred due to interference with the enzymatic activity of
SCD1, then this cell death could also be rescued by exogenous
supplementation of oleic acid. We therefore exposed the cells
to PluriSIn #1 in the presence of increasing concentrations of
oleic acid. Remarkably, medium supplementation with oleic
acid led to a concentration-dependent suppression of cell death,
with full rescue observed in the presence of high concentrations
of this fatty acid (Figures 4E and 4F). Collectively, these data
reveal that the survival of hPSCs depends on the normal activity
of SCD1 and that hPSCs are highly sensitive to perturbations in
the MUFA biosynthesis pathway. Similarly to some cancer cell
lines, inhibition of SCD1 activity in hPSCs leads to MUFA deple-
tion, which induces ER stress and UPR followed by translational
attenuation, and ultimately results in apoptosis of the cells
(see Discussion section). To further confirm that SCD1 inhibition
underlies the cellular perturbations observed after the exposure
of hPSCs to PluriSIn #1, we examined whether the SCD1
inhibitor A939572 would recapitulate these cellular responses.
We found that, similarly to PluriSIn #1, exposure of hPSCs to
A939572 results in ER stress, protein synthesis inhibition, and
apoptosis (Figures S5A–S5C).
The finding that nine of 15 PluriSIns share a common moiety,
phenylhydrazine, and seven of them are N-acyl phenylhydrazine
derivatives suggested that these compounds might work
through the same molecular target and/or mechanism of action.
We thus examined whether four other PluriSIns also work
through the inhibition of SCD1: two PluriSIns with N-acyl phenyl-
hydrazine in their structure (PluriSIn #5 and PluriSIn #6) and two
PluriSIns that do not contain this phenylhydrazine (PluriSIn #2
and PluriSIn #3). HPSCswere exposed to each of these PluriSIns
for 24 hr, at the presence or absence of oleic acid, and cell
viability was then quantified. Remarkably, oleate prevented
PluriSIn #5- and PluriSIn #6-induced hPSC death but had no
effect on the cell death induced by PluriSIn #2 or PluriSIn #3
(Figure S5D). These results imply that some, but not all, of the
PluriSIns work through the inhibition of SCD1, and that the
commonmoiety may indeed be related to this effect. Supporting
this hypothesis, PluriSIn #6 conferred gene expression alter-
ations that were highly similar to those conferred by PluriSIn #1
(Figure 3B) and that predicted SCD1 inhibition (Figure 4A), UPR
(Figure 3H), PSI (Figure S5E), and apoptosis (Figure 3C). Further
research is warranted to elucidate the mechanism of action and
the molecular targets of other PluriSIns.
PluriSIn #1 Compromises Mouse Embryonic
Development
Mouse PSCs (mPSCs) are widely used in pluripotency-related
research, and generating pure cultures of mPSC-differentiated
cells is therefore of great importance. We were thus interested
to determine whether mPSCs are also sensitive to PluriSIns.174 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier IncR1 Oct4-GFP mouse ESCs were plated in 96-well plates and
exposed to PluriSIns at 20 mM concentration, and the viability
of the cells was then assessed at 24 hr, 48 hr, and 72 hr,
using luminescent viability assay and fluorescence microscopy
imaging. The four examined PluriSIns induced massive cell
death in mPSCs, indicating that PluriSIn sensitivity is shared by
mouse and human PSCs (Figures 5A and 5B). It is worth noting,
however, that inhibition of mPSCs by PluriSIns was not as
efficient as that of hPSCs and required a longer exposure to
the compounds (Figures 5A and 5B).
We next took advantage of the mouse system to examine
whether PluriSIn #1 is cytotoxic to the inner cell mass cells
(ICMCs), from which ESCs are derived. We figured that if
SCD1 activity was crucial to pluripotent cells in vivo, then
PluriSIn #1 would be cytotoxic to the ICMCs and would thus
compromise normal embryonic development. We cultured
mouse embryos from the two-cell stage, exposed them to
PluriSIn #1 at the morula stage, and followed their development.
All of the control embryos (18/18) developed into blastocysts
with large and distinct (grade A/B) ICMCs (Figures 5C and 5D).
In contrast, only 40% of the embryos exposed to PluriSIn #1
developed into high-quality blastocysts (7/17), whereas the
rest of these embryos developed into blastocysts with no
distinguished ICMCs (grade C, 6/17) or were ‘‘stuck’’ at the
morula stage (4/17) (Figures 5C and 5D). This marked difference
in the embryonic fate after exposure to the compound is highly
significant (p = 0.0001) and indicates that PluriSIn #1 is indeed
cytotoxic to ICMCs and precludes normal development of
the blastocyst. We next examined whether oleic acid supple-
mentation would rescue blastocyst formation; most embryos
exposed to PluriSIn #1 in the presence of oleic acid developed
into high-quality blastocysts (5/7) (Figures S6A and 5D), a
much greater proportion than in the embryos exposed to
PluriSIn #1 alone (71% versus 41%, respectively). Finally, we
examined whether blastocyst formation would also be hindered
by the SCD1 inhibitor A939572; indeed, only half of the embryos
exposed to this compound developed into high-grade blasto-
cysts (5/9, p = 0.007), and this proportion increased after oleic
acid supplementation (5/7) (Figures S6A and S6B). These results
suggest that the dependence of PSCs on SCD1 is inherent to
the pluripotent state, both in vitro and in vivo.
PluriSIn #1 Can Prevent Teratoma Formation
As the ultimate goal of selective hPSC inhibitors is to prevent
teratoma formation by efficiently removing residual undifferenti-
ated cells from culture, we next turned to demonstrate the
usefulness of PluriSIn application for this aim, using in vitro and
in vivo assays. We tested the compounds in various culture
conditions and exposure durations and found that PluriSIns
weremore potent in smaller (384- or 96-well) plates than in larger
(6-well or 10 cm) plates, and in low cell densities than in high cell
densities, probably due to a protective effect conferred by
large colonies (Figure S7A). For the complete elimination of
undifferentiated cells cultured in 6-well plates, 48 hr exposure
of the cells to PluriSIn #1 at 20 mM was required (Figure S7B).
Of note, PluriSIns were also more potent when cells were
cultured on matrigel-coated plates without feeder cells, using
mTeSR1-definedmedium; hPSCs cultured onMEFs with regular
ESC medium were less sensitive to PluriSIns, possibly due to.
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Figure 5. PluriSIns Inhibit Mouse Pluripotent Stem Cells and Hinder Mouse Embryonic Development
(A) Fluorescence microscopy imaging of undifferentiated R1 Oct4-GFP mouse ESCs. NC, negative control, 0.5% DMSO; PC, positive control, amsacrine
hydrochloride at 5 mM. Scale bar represents 100 mm.
(B) Quantification of the relative number of viable mouse ESCs under DMSO control conditions or after treatment with various PluriSIns (20 mM) for 72 hr. Data are
presented as mean ± SD.
(C) Representative images of mouse embryos developed in vitro from the two-cell stage (1.5 dpc) to the mature blastocyst stage (4.5 dpc). At the morula stage
(3.5 dpc), embryos were exposed for 24 hr to PluriSIn #1 (20 mM) or to control conditions (0.2%DMSOor without DMSO at all). All 18 embryos grown under control
conditions developed into mature blastocysts with distinct inner cell mass, whereas only seven of 17 embryos grown in the presence of PluriSIn #1 developed
into such blastocysts (p = 0.0001); ICM, inner cell mass. Note that embryos without inner cell mass, and embryos stuck at the morula stage, were observed
upon PluriSIn #1 treatment. Scale bar represents 100 mm.
(D) A stacked column graph presenting the percentage of grade A/B, grade C, and hindered blastocysts, after the exposure of mouse embryos to control
conditions, to PluriSIn #1 (20 mM) alone, or to PluriSIn #1 together with oleic acid (100 mM). See also Figure S6.
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the MEFs (Figure S7C).
We next set out to determine the number of residual undiffer-
entiated cells that remain in culture after PluriSIn #1 application
in vitro, and whether these remaining cells would be tumorigenic
in vivo. Fluorescence-activated cell sorting (FACS) analysis of
mixed cell populations cultured in 6-well plates and exposed
to PluriSIn #1 for 48 hr suggested that over 99% of the pluripo-
tent cells are eliminated from culture, based on their staining to
the pluripotent marker TRA-1-60 (Figure 6A). Fluorescence
microscopy imaging of CSES-SO2/3 cells after treatment
confirmed that almost all OCT4-expressing cells were eliminated
(Figure 6B). We then mixed hPSCs with differentiated cells (a
customary methodology for teratoma formation analysis; Hentze
et al., 2009; Tang et al., 2011) and examined the ability of PluriSIn
#1 to prevent teratomas. hPSCs were differentiated for 10 days,
mixed with undifferentiated cells (1:1), exposed to PluriSIn #1 for
48 hr, and then injected subcutaneously into immune-com-
promised mice. We used the highly immune-deficient strain
NOD-SCID IL2Rg/ mice, which was previously shown to beCeespecially susceptible to develop human-derived tumors (Quin-
tana et al., 2008). Each mouse was injected with PluriSIn #1-
treated cells into one side of its body and DMSO-treated control
cells into the other side. Importantly, the same total number of
cells (1 3 106) was injected into both sides. Mice were sacri-
ficed after 6 weeks, and teratoma formation was assessed.
As expected, all the injected mice developed teratomas only
in the side injected with control hPSCs (Figures 6C, 6D, S7D,
and S7E), whereas no teratomas were generated in any of the
mice transplanted with PluriSIn #1-treated hPSCs (Figures 6E,
S7D, and S7E). Treatment of the cells with the SCD1 inhibitor
A939572 recapitulated the preventive effect of PluriSIn #1 (Fig-
ure S7F). To verify that PluriSIn #1-treated hPSCs do not
generate teratomas even after prolonged time in vivo, the cells
were injected into four mice subcutaneously, and teratoma
formation was monitored every week for 16 weeks. No tera-
tomas were generated in any of these mice throughout
the entire time course of the experiment. We conclude that
PluriSIn #1 can efficiently remove tumorigenic undifferentiated
cells from cultures of hPSC-derived cells.ll Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Inc. 175
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Figure 6. PluriSIn #1 Prevents Teratoma Formation from Undifferentiated hPSCs
(A) Human ESCs were differentiated in culture for 10 days and were thenmixed with undifferentiated ESCs in 6-well plates and exposed to PluriSIn #1 or to DMSO
control conditions for 48 hr. Cells were stained with an antibody against TRA-1-60, and the fraction of remaining undifferentiated cells in culture was examined
by FACS analysis. Whereas a large fraction of TRA-1-60-positive cells existed in the control culture (red), the PluriSIn #1-treated culture (blue) was comprised
of differentiated cells only (with less than 1% TRA-1-60-positive cells).
(B) Fluorescence microscopy imaging of CSES-SO2/3 cells grown in 6-well plates, after 48 hr exposure to DMSO control conditions or to PluriSIn #1 (20 mM).
OCT4-positive cells were not detected in culture after PluriSIn #1 treatment (red fluorescence). Scale bars represent 200 mm.
(C) Human ESCs and iPSCs were spontaneously differentiated in culture for 10 days and were then mixed 1:1 with undifferentiated cells. After 48 hr exposure
to PluriSIn #1, cells were harvested and injected subcutaneously into NOD-SCID IL2Rg/. Eachmouse was injected with PluriSIn #1-treated cells into one side
of its back and control-treated cells into the other side. The same total number of cells (approximately one million) was injected into both sides. Six weeks later,
mice were sacrificed. Only the control cells generated teratomas (encircled), whereas the injected PluriSIn #1-treated cells did not (arrows indicate the locations
of their injections).
(D) Histology of ESC- and iPSC-derived teratomas stained with hematoxylin and eosin. From left to right: representative gut epithelium, skeletal muscle,
and neural rosette structures are presented. Scale bar represents 100 mm.
(E) A summary of teratoma formation experiments, showing that all of the control cells—but none of the cells treatedwith PluriSIn #1—formed teratomas. See also
Figure S7.
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We performed a high-throughput screen of 52,448 small mole-
cules and identified 696 compounds that efficiently and rapidly
eliminate human ESCs and iPSCs in a concentration-dependent
manner. We then counter screened these compounds against
nine cell types of all developmental stages and of all germ
layers and identified small molecules that selectively eliminated
hPSCs, without reducing the viability of any other cell type,
including other stem and progenitor cells. We thus termed
these compounds pluripotent-specific inhibitors (PluriSIns). In
order to identify the molecular target and the pathway perturbed
by these molecules, we first took a toxicogenomic approach
and explored the gene expression changes conferred by expo-
sure of hPSCs to selected PluriSIns. Gene expression patterns
of hPSCs after 12 hr exposure to PluriSIn #1 suggested that
it may lead to ER stress, UPR, PSI, and apoptosis. Direct
biochemical assays revealed that PluriSIn #1 inhibits SCD1,
the key enzyme in the generation of MUFA, and that this inhibi-
tion in hPSCs indeed results in ER stress, UPR, PSI, and finally
apoptosis. Supplementation of the medium with oleic acid, the
product of SCD1 activity, completely rescued the PluriSIn #1-176 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Incinduced cell death, indicating that SCD1 inhibition is the direct
cause of death.
These data reveal a previously uncharacterized dependence
of hPSCs on SCD1 activity, related to that seen previously in
human cancer cell lines. This dependence is evolutionarily
conserved, as PluriSIn #1 was cytotoxic to mPSCs as well.
Importantly, PluriSIn #1 was also cytotoxic to the ICMCs of
developing mouse blastocysts, suggesting that the dependence
of PSCs on SCD1 is inherent to the pluripotent state. Interest-
ingly, Scd1 knockout is not embryonic lethal in mice (Miyazaki
et al., 2000), probably due to its functional redundancy with
three other mouse Scd isoforms (Scd2, Scd3, and Scd4)
that share about 85% amino acid identity with the protein
product of Scd1 (Ntambi et al., 2004) and that do not exist in
humans.
Finally, we demonstrated the usefulness of PluriSIns for the
complete removal of tumorigenic hPSCs from culture and
prevention of teratoma formation. The teratoma experiments
were performed by mixing undifferentiated cells with their
differentiated progeny, rather than by transplanting differenti-
ated cultures per se. This approach is well accepted in the
field (Hentze et al., 2009; Tang et al., 2011), as the baseline.
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Figure 7. A Model of PluriSIn #1 Mechanism of Action
A model of PluriSIn #1 mechanism of action, based on all presented data.
PluriSIn #1 inhibits SCD1 activity in hPSCs, thereby altering the balance
between its substrates and its products, leading to the accumulation of
palmitate and stearate and to the deprivation of oleate. This inhibition selec-
tively leads to ER stress, unfolded protein response, and translational atten-
uation in hPSCs, which finally result in apoptosis. See the Discussion section
for elaborated explanation of the model.
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entiated cultures is low to begin with (Miura et al., 2009; Roy
et al., 2006; Xie et al., 2007). The results from these experiments
show that PluriSIns can be used to drastically reduce the risk
of tumor formation after injection of hPSC-derived cells into
patients and can thus considerably improve the safety of
hPSC-based treatments.
Lipids were previously reported to regulate the self-renewal of
human ESCs (Garcia-Gonzalo and Izpisu´a Belmonte, 2008), but
no specific lipid was determined to be essential for the survival
of these cells. Here we found that the biosynthesis of the MUFA
oleate by the enzyme SCD1 is a vital process in hPSCs. As the
expression level of SCD1 in hPSCs is comparable with that of
other cell types, such as fibroblasts and neural cells, and is lower
than that in hepatocytes (Assou et al., 2007), the specific cytotox-
icity of PluriSIn #1 toward hPSCs cannot be explained by
a uniquely high expression of this protein in hPSCs. Importantly,
although media composition can influence the sensitivity of
hPSCs to PluriSIn #1 (as is evident by the oleate supplementation
experiments), this cannot explain the selective cytotoxic effect
either: the definedmediummTeSR1 contains oleate at a concen-
tration of 10 mM (Ludwig et al., 2006), whereas the serum-free
Dulbecco’s modified Eagle’s medium that we used for endo-
dermal differentiation did not contain any oleic acid; nonetheless,
hPSCs grown with mTeSR are highly sensitive to PluriSIn #1,
while eight day-differentiated cells are completely resistant to
it. Moreover, when we cultured several PluriSIn #1-resistant cell
types in human ESC medium and exposed them to PluriSIn #1,
the compound still did not have any cytotoxic effect on these
cells (Figures S4C and S4D), ruling out the medium as an impor-
tant factor in the differential PluriSIn #1-induced lethality.
Previous studies in various cell types have shown that
accumulation of saturated fatty acids, SCD1 substrates, andCedepletion of MUFA, SCD1 product, can induce ER stress and
UPR by several mechanisms: generation of reactive oxygen
species (ROS), which leads to ER calcium depletion (Borradaile
et al., 2006a); alteration of the ERmembrane composition, which
results in a dramatic impairment of its structure and integrity
(Borradaile et al., 2006b); and impairment of the ER-to-Golgi
trafficking, which results in the build-up of proteins in the ER
(Preston et al., 2009). Oleic acid, the product of SCD1 activity,
was shown to compete with the saturated fatty acids, block
the abnormal lipid distribution, and attenuate ER stress (Hapala
et al., 2011; Peng et al., 2011). Our findings reveal that hPSCs
require oleate for their survival and are thus highly sensitive
to SCD1 inhibition, which activates a cascade of events that
culminates in the death of these cells (Figure 7). Importantly,
differentiated cell types are much less sensitive to SCD1 inhibi-
tion, and this difference seems to underlie the selective cell
death conferred by SCD1 inhibitors. According to our proposed
model, the selectivity of PluriSIn #1 is determined already early
on in the cascade of events (i.e., by the selective response to
SCD1 inhibition). Consistent with this model, general inducers
of ER stress and PSI lead to hPSC death, but this effect is not
selective and cannot be rescued by oleate (Figure S4E).
The high sensitivity of hPSCs to SCD1 inhibition may be, at
least in part, due to their increased sensitivity to ER stress in
general. The levels of hallmark UPR markers were shown to
be high in hPSCs and decrease upon differentiation (Liu et al.,
2012), suggesting that hPSCs experience ER stress under
normal culture conditions. In line with previous reports, we found
that hPSCs indeed express higher levels of the UPR hallmarks
sXBP1 and peIF2a, when compared to differentiated cells
(Figure 3I). Hence, a further increase in the already high ER
stress levels in these cells may immediately induce their
apoptosis. Of note, the activity of another metabolic enzyme,
the mithochondrial threonine dehydrogenase, was previously
shown to be essential for the survival of mPSCs (Alexander
et al., 2011). Aswe show here that hPSCs are extremely sensitive
to perturbation of MUFA biogenesis, it is tempting to speculate
that the unique metabolic state of hPSCs may make them espe-
cially amenable to perturbations of metabolic processes.
PluriSIns are potent small molecules to selectively eliminate
hPSCs. This chemical approach to ablate tumorigenic hPSCs
from culture is superior to previously described methods as it
is more rapid, efficient, and robust. It does not involve any
genetic manipulation of the cells, which may affect genomic
stability and undergo spontaneous reversion. It also does not
require cell sorting and can thus be applied to complex differen-
tiation protocols that do not allow for single-cell dissociation.
As we demonstrate, PluriSIns can prevent teratoma formation
by treatment of the cells prior to their transplantation. Hence,
they should promote the safety of hPSC-based treatments and
facilitate the safe transplantation of larger cell numbers. It will
be interesting to examine whether PluriSIns might also be
applied in vivo, both for the elimination of hPSC-derived tumors
and against germ cell tumors. Future studies should also ex-
amine the compatibility of PluriSIns with specific clinically
relevant differentiation protocols and determine the optimal
concentrations and exposure durations for each individual
case. The mechanistic understanding of the PluriSIn mode of
action, i.e., the functionally unique role of SCD1 revealed inll Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier Inc. 177
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to support the most effective elimination of these cells. Lastly,
the finding that this mechanism is also crucial during early
mammalian development paves the way to future studies of
the unique metabolism in preimplantation embryos.EXPERIMENTAL PROCEDURES
Cell Culture
Human ESC lines H9, CSES2, and CSES2-SO2/3, iPSC line BJ-iPS28, neuro-
blastoma cell line Kelly, hepatocarcinoma cell line Huh-7, cervical carcinoma
cell line HeLa, teratocarcinoma cell line NTERA-2, and immortalized BJ fibro-
blasts cell line were cultured using standard conditions. Human iPSC-derived
cardiomyocytes were purchased fromCellular Dynamics International. Human
ESC-derived hepatocytes were purchased from Cellartis. R1 Oct4-GFP
mouse ESCs were cultured using standard conditions. See Supplemental
Experimental Procedures for full culture and differentiation protocols.Chemical Library Screening
The CellTiter-Glo luminescent cell viability assay (Promega) was imple-
mented as an HTS assay for chemical library screen in a 384-well format.
For primary screen, a 52,448 compound screening library assembled with
Roche internal compounds was tested in a 384-well format. For confirmation
screens, counter screens, and compound profiling screens, compounds that
were defined as ‘‘hits’’ were obtained from Roche proprietary compound
inventory. See Supplemental Experimental Procedures for full details of the
screen.Global Gene Expression Analysis
Total RNA was extracted and subjected to Human Genome U133A 2.0 micro-
array platform (Affymetrix). Arrays were normalized using MAS5 algorithm
in the Affymetrix Expression Console. See Supplemental Experimental
Procedures.SCD1 Activity Measurement
SCD1 activity was directly measured by [1-14C] Stearic Acid labeling, followed
by quantification of free [1-14C] Stearic Acid (substrate) and [1-14C] Oleic Acid
(formed product). All solvents and reagents were purchased from Sigma-
Aldrich. Experiments were performed in triplicates. See Supplemental
Experimental Procedures for full details of the assay.SCD1 Inhibition and Oleic Acid Rescue Assay
SCD1 inhibition was performed either by commercial SCD1 inhibitors or
by siRNA against human SCD1. For the rescue assay, cells were treated
with PluriSIns in the presence or absence of oleate. See Supplemental Exper-
imental Procedures.In Vitro Embryonic Development Experiments
Two-cell embryos were collected by standard procedure, exposed to small
molecules at the presence or absence of oleate, and analyzed at4 days post-
coitum (dpc) and 4.5 dpc. See Supplemental Experimental Procedures for
a full description of the procedure.Teratoma Formation and Analysis
Cells were injected subcutaneously to the back of NOD-SCID IL2Rg/mice
(Jackson Laboratory). Six weeks after injection, mice were sacrificed, and the
formation of tumors was examined. See Supplemental Experimental Proce-
dures for full details.ACCESSION NUMBERS
Microarray data have been deposited under Gene Expression Omnibus (GEO)
accession number GSE37040.178 Cell Stem Cell 12, 167–179, February 7, 2013 ª2013 Elsevier IncSUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2012.11.015.
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